COVID-19-related arrhythmias and the possible effects of ranolazine
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Medical Hypotheses
- Vol. 149, 110545
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazineEP Europace, 2012
- The Use of Ranolazine to Facilitate Electrical Cardioversion in Cardioversion‐Resistant Patients: A Case SeriesPacing and Clinical Electrophysiology, 2012
- Electrophysiologic basis for the antiarrhythmic actions of ranolazineHeart Rhythm, 2011
- Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2Journal of General Virology, 2008
- Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparationsHeart Rhythm, 2008
- SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent ICaL, [Ca2+]i transient, and APD increase in cardiomyocytesJournal of Molecular and Cellular Cardiology, 2007
- Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial FibrillationCirculation, 2007
- Clinical Pharmacokinetics of RanolazineClinical Pharmacokinetics, 2006
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- Impairment of HERG K+ Channel Function by Tumor Necrosis Factor-αJournal of Biological Chemistry, 2004